Novartis Gets Positive Test Results for Cholesterol Drug

By Christian Moess Laursen

Novartis received positive results from a phase three study testing its Leqvio cholesterol-management drug as a standalone treatment for lowering cholesterol in patients at risk of atherosclerotic cardiovascular disease, or ASCVD.

The Swiss pharma company said Wednesday that the trial met its primary end points, showing that Leqvio significantly reduced low-density lipoprotein cholesterol levels.

"This trial adds to the growing body of evidence for Leqvio across the full spectrum of ASCVD," Chief Medical Officer Shreeram Aradhye said.

Additionally, Novartis is conducting several other studies, exploring Leqvio's use in both primary and secondary prevention of ASCVD. These studies aim to further solidify Leqvio's role in cholesterol management, with key results expected between 2024 and 2027.

Write to Christian Moess Laursen at christian.moess@wsj.com

(END) Dow Jones Newswires

August 28, 2024 01:59 ET (05:59 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.